483
Lonza AGFDA 483 - Lonza AG - December 15, 2017
Record Details
An FDA inspection of Lonza AG in Visp, Switzerland, a drug substance manufacturer, revealed one observation. The firm's master production instructions were found to be deficient, specifically lacking defined time and temperature limits for critical processing steps of a starting material. This indicates a potential issue with process control and consistency in manufacturing.
Open in Dashboard
ID · 8a04ca07-4b1d-4652-b808-fa39c435dba7